The regenerative potential of fibroblasts in a new diabetes-induced delayed humanised wound healing model

• Published in: Experimental dermatology Vol. 22; no. 3; pp. 195 - 201
• Main Authors: Martínez-Santamaría, Lucía, Conti, Claudio J., Llames, Sara, García, Eva, Retamosa, Luisa, Holguín, Almudena, Illera, Nuria, Duarte, Blanca, Camblor, Lino, Llaneza, José M., Jorcano, José L., Larcher, Fernando, Meana, Álvaro, Escámez, María J., Del Río, Marcela
• Format: Journal Article
• Language: English
• Published: Denmark Blackwell Publishing Ltd 01-03-2013
• Subjects: animal models; Animals; Bioengineering - methods; Cell- and Tissue-Based Therapy - methods; Cells, Cultured; delayed wound healing; Diabetes Mellitus, Experimental - chemically induced; Diabetes Mellitus, Experimental - pathology; Diabetes Mellitus, Experimental - physiopathology; diabetic wounds; Disease Models, Animal; Female; fibroblasts; Fibroblasts - cytology; Fibroblasts - physiology; Humans; Mice; Mice, Nude; Regeneration - physiology; Skin Physiological Phenomena; Streptozocin - adverse effects; Time Factors; tissue engineering; Tissue Scaffolds; Transplantation, Heterologous; Wound Healing - physiology
• ISSN: 0906-6705; 1600-0625
• DOI: 10.1111/exd.12097

Cutaneous diabetic wounds greatly affect the quality of life of patients, causing a substantial economic impact on the healthcare system. The limited clinical success of conventional treatments is mainly attributed to the lack of knowledge of the pathogenic mechanisms related to chronic ulceration. Therefore, management of diabetic ulcers remains a challenging clinical issue. Within this context, reliable animal models that recapitulate situations of impaired wound healing have become essential. In this study, we established a new in vivo humanised model of delayed wound healing in a diabetic context that reproduces the main features of the human disease. Diabetes was induced by multiple low doses of streptozotocin in bioengineered human‐skin‐engrafted immunodeficient mice. The significant delay in wound closure exhibited in diabetic wounds was mainly attributed to alterations in the granulation tissue formation and resolution, involving defects in wound bed maturation, vascularisation, inflammatory response and collagen deposition. In the new model, a cell‐based wound therapy consisting of the application of plasma‐derived fibrin dermal scaffolds containing fibroblasts consistently improved the healing response by triggering granulation tissue maturation and further providing a suitable matrix for migrating keratinocytes during wound re‐epithelialisation. The present preclinical wound healing model was able to shed light on the biological processes responsible for the improvement achieved, and these findings can be extended for designing new therapeutic approaches with clinical relevance.